Home / Market News / $GILD
benzinga Corporate Catalyst Impact 55/100 ● negative

Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Oct 7, 2026, 2:34 PM UTC · Primary ticker $GILD

Morgan Stanley analyst Matthew Harrison reiterated an 'Overweight' rating on Gilead Sciences but slightly reduced the price target from $165 to $163. This indicates a continued positive outlook on the company's fundamentals despite a minor adjustment to its valuation, suggesting a stable but not significantly bullish shift in analyst sentiment.

Morgan Stanley's analyst Matthew Harrison maintained an 'Overweight' rating on Gilead Sciences, signaling a continued positive long-term outlook for the company. However, the slight reduction in the price target from $165 to $163 suggests a minor recalibration of valuation, possibly due to updated financial models, market conditions, or competitive landscape. This news primarily affects Gilead Sciences, as it reflects a key institutional analyst's view. In the short term, the impact is likely neutral to slightly negative as the price target reduction might temper some bullish sentiment, but the maintained 'Overweight' rating prevents a significant downturn. Long-term implications are minimal, as the core investment thesis remains intact. For traders, the key risk is that other analysts might follow suit with similar minor price target adjustments, potentially creating slight downward pressure, while the opportunity lies in the stability offered by the maintained positive rating.

$GILD neutral Analyst rating maintained, price target slightly lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.